HPV self-sampling as primary screening test in sub-Saharan Africa: Implication for a triaging strategy

International Journal of Cancer

Volumn 135, Issue 8, 2014, Pages 1911-1917

  Untiet, Sarah ^a   Vassilakos, Pierre ^b   McCarey, Catherine ^a   Tebeu, Pierre Marie ^c   Kengne Fosso, Gisèle ^c   Menoud, Pierre Alain ^d   Boulvain, Michel ^a   Navarria, Isabelle ^a   Petignat, Patrick ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b WHO Collaborating Centre in Education and Research in Human Reproduction   (Switzerland)

^c University Hospitals   (Cameroon)

^d Unilabs   (France)

Author keywords

Cameroon; cervical cancer screening; human papillomavirus; low resource country; screen and treat; self sampling

Indexed keywords

ADULT; AFRICA SOUTH OF THE SAHARA; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; EDUCATION; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PHYSICIAN; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; SELF EXAMINATION; SENSITIVITY AND SPECIFICITY; SEXUAL INTERCOURSE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERY ELDERLY; WART VIRUS;

CAMEROON; CERVICAL CANCER SCREENING; HUMAN PAPILLOMAVIRUS; LOW RESOURCE COUNTRY; SCREEN AND TREAT; SELF-SAMPLING;

ADULT; AGED; AGED, 80 AND OVER; CAMEROON; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; SELF CARE; TRIAGE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84905754631     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28834     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Sankaranarayanan R, Thara S, Esmy PO, et al. Cervical cancer: screening and therapeutic perspectives. Med Princ Pract 2008; 17: 351-64.
3. US Census. Demographic Indicators. Country Summary, Washington, DC: US Census, 2007.
4. Barrere M,. Santé de la mère et de l'enfant. In: Institut National de la Statistique Ministere de la Planification dlPdDedlAdTY, ed. vol. 2012. Cameroun and ORC Macro Calverton, Maryland, Cameroon: DHS, 2004-Final Report (French), 2005: Monograph.
5. Mossoko JJ, Afana GAN,. Prévalence du VIH et facteurs associés. In: Institut National de la Statistique Ministere de la Planification dlPdDedlAdTY, ed. vol. 2012. Cameroun and ORC Macro Calverton, Maryland, Cameroon: DHS, 2004-Final Report (French), 2005: Monograph.
6. WHO/ICO. Information Centre on HPV and Cervical Cancer (HPV Information Centre)-Human Papillomavirus and Related Cancers in Cameroon. Summary Report, 2010.
7. Tebeu PM, Major AL, Rapiti E, et al. The attitude and knowledge of cervical cancer by Cameroonian women; a clinical survey conducted in Maroua, the capital of Far North Province of Cameroon. Int J Gynecol Cancer 2008; 18: 761-5.
8. Robyr R, Nazeer S, Vassilakos P, et al. Feasibility of cytology-based cervical cancer screening in rural Cameroon. Acta Cytol 2002; 46: 1110-6.
9. WHO. Comprehensive cervical cancer control-a guide to essential practice, WHO, Geneva, Switzerland, 2006.
10. Sauvaget C, Fayette JM, Muwonge R, et al. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet 2011; 113: 14-24.
11. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
12. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
13. Bigras G, de Marval F,. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer 2005; 93: 575-81.
14. Petignat P, Vassilakos P,. Is it time to introduce HPV self-sampling for primary cervical cancer screening? J Natl Cancer Inst 2012; 104: 166-7.
15. Zhao FH, Lewkowitz AK, Chen F, et al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. J Natl Cancer Inst 2012; 104: 178-88.
16. Petignat P, Faltin DL, Bruchim I, et al,. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing?. A systematic review and meta-analysis. Gynecol Oncol 2007; 105: 530-5.
17. Franco EL,. A new generation of studies of human papillomavirus DNA testing in cervical cancer screening. J Natl Cancer Inst 2009; 101: 1600-1.
18. van de Wijgert J, Altini L, Jones H, et al. Two methods of self-sampling compared to clinician sampling to detect reproductive tract infections in Gugulethu, South Africa. Sex Transm Dis 2006; 33: 516-23.
19. Berner A, Hassel SB, Tebeu PM, et al. Human papillomavirus self-sampling in Cameroon: women's uncertainties over the reliability of the method are barriers to acceptance. J Low Genit Tract Dis 2013; 17: 235-41.
20. Pezzullo JC,. statpages.org, vol. 2012. http://statpages.org/index.html. Accessed 21 May 2012.
21. Dean AG, Sullivan KM, Soe MM,. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1., vol. 2012, 2011.
22. Gage JC, Ajenifuja KO, Wentzensen NA, et al. The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer 2012; 130: 2111-7.
23. Morris DL, McLean CH, Bishop SL, et al. A comparison of the evaluation and treatment of cervical dysplasia by gynecologists and nurse practitioners. Nurse Practitioner 1998; 23: 101-2, 08-10, 13-4.
24. Chamot E, Kristensen S, Stringer JS, et al. Are treatments for cervical precancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs?. A systematic review. BMC Women's Health 2010; 10: 11.
25. Sankaranarayanan R, Gaffikin L, Jacob M, et al. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005; 89 (Suppl 2): S4-S12.
26. Bruni L, Diaz M, Castellsague X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99.
27. Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106: 896-904.
28. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
29. Keita N, Clifford GM, Koulibaly M, et al. HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 2009; 101: 202-8.
30. Thomas JO, Herrero R, Omigbodun AA, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004; 90: 638-45.
31. Wall SR, Scherf CF, Morison L, et al. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. Br J Cancer 2005; 93: 1068-76.